fbpx

ADVERTISEMENT

ADVERTISEMENT

Non-Hodgkin’s Disease

Updated : April 26, 2022





Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

 

carmustine

150 - 200

mg/m^2

Intravenous (IV)

as a single dose for at least six weeks
Or divided into daily injections as a dose of 75-100 mg/m2 given IV for every two days



doxorubicin

50

mg/m^2

Intravenous (IV)

on day 1 every 21 days in combination with cyclophosphamide, vincristine, and prednisone.



tositumomab 

Dosimetric dose:

450

mg

Intravenous (IV)

infuse over 1 hour


next I-131 tositumomab five mCi I-131 + 35 mg protein Intravenous (IV) infusion for 20 minutes
Therapeutic dose:
450 mg Intravenous (IV) infuse over 1 hour, next I-131 tositumomab dose determined to produce 75 cGy total body irradiation for patients with average platelet count 7 -14 days after a dosimetric dose



 

doxorubicin

25

mg/m^2

Intravenous (IV)

per day infused over 1 hour on days 4 and 5 of a 21- to 28- day cycle in combination with cyclophosphamide, prednisone, methotrexate, and vincristine (dose adjustment may depend on neutrophil recovery).



 

Media Gallary

References

ADVERTISEMENT 

Non-Hodgkin’s Disease

Updated : April 26, 2022




carmustine

150 - 200

mg/m^2

Intravenous (IV)

as a single dose for at least six weeks
Or divided into daily injections as a dose of 75-100 mg/m2 given IV for every two days



doxorubicin

50

mg/m^2

Intravenous (IV)

on day 1 every 21 days in combination with cyclophosphamide, vincristine, and prednisone.



tositumomab 

Dosimetric dose:

450

mg

Intravenous (IV)

infuse over 1 hour


next I-131 tositumomab five mCi I-131 + 35 mg protein Intravenous (IV) infusion for 20 minutes
Therapeutic dose:
450 mg Intravenous (IV) infuse over 1 hour, next I-131 tositumomab dose determined to produce 75 cGy total body irradiation for patients with average platelet count 7 -14 days after a dosimetric dose



doxorubicin

25

mg/m^2

Intravenous (IV)

per day infused over 1 hour on days 4 and 5 of a 21- to 28- day cycle in combination with cyclophosphamide, prednisone, methotrexate, and vincristine (dose adjustment may depend on neutrophil recovery).



Free CME credits

Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.

Digital Certificate PDF

On course completion, you will receive a full-sized presentation quality digital certificate.

medtigo Simulation

A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.

medtigo Points

medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
 
  • Registration with medtigo = 10 points
  • 1 visit to medtigo’s website = 1 point
  • Interacting with medtigo posts (through comments/clinical cases etc.) = 5 points
  • Attempting a game = 1 point
  • Community Forum post/reply = 5 points

    *Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.

All Your Certificates in One Place

When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.

Our Certificate Courses